See more : APG|SGA SA (0QN0.L) Income Statement Analysis – Financial Results
Complete financial analysis of COMPASS Pathways plc (CMPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of COMPASS Pathways plc, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Meiko Electronics Co., Ltd. (6787.T) Income Statement Analysis – Financial Results
- Euro Multivision Limited (EUROMULTI.NS) Income Statement Analysis – Financial Results
- Nishoku Technology Inc. (3679.TW) Income Statement Analysis – Financial Results
- CRCC High-Tech Equipment Corporation Limited (1786.HK) Income Statement Analysis – Financial Results
- Development Advance Solution Co.,Ltd. (058730.KS) Income Statement Analysis – Financial Results
COMPASS Pathways plc (CMPS)
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 0.00 |
| Gross Profit | -242.94K | -329.80K | -174.98K | -112.00K | -63.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 87.52M | 65.05M | 44.03M | 23.37M | 12.56M | 8.92M |
| General & Administrative | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Other Expenses | 0.00 | -14.42M | -9.65M | -4.25M | -2.73M | -2.68M |
| Operating Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Cost & Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Interest Income | 0.00 | 0.00 | 40.00 | 319.00 | 73.00 | 0.00 |
| Interest Expense | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 22.00K |
| EBITDA | -123.80M | -110.40M | -83.22M | -47.04M | -18.39M | -10.52M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -136.92M | -110.40M | -83.22M | -51.39M | -21.18M | -12.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.24M | 19.31M | 11.68M | -8.91M | 1.58M | -716.00K |
| Income Before Tax | -117.68M | -91.10M | -71.54M | -60.30M | -19.60M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 780.00K | 408.00K | 199.00K | 32.00K | 15.00K | -716.00K |
| Net Income | -118.46M | -91.51M | -71.74M | -60.33M | -19.61M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| EPS Diluted | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| Weighted Avg Shares Out | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
| Weighted Avg Shares Out (Dil) | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting?
Analysts are expecting Compass Pathways' stock to blast off soon. There aren't actually any expected near-term events which might drive such a rise.
The 3 Best Psychedelic Stocks to Buy Now
Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly become a hot topic in the mental health...
FDA issues guidance on psychedelic drug clinical trials
The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies investigating the drugs' potential to treat psychiatric and substance-use disorders and other medical conditions. Psychedelics are increasingly drawing...
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.
Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive interview. The money will help fund academic institutions investigating psychedelics' potential to treat...
COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences
LONDON, June 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the following investor conferences:
Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients
Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.
COMPASS Pathways plc (CMPS) Q1 2023 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Steve Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Guy Goodwin - Chief Medical Officer Mike...
COMPASS Pathways beats earnings forecast in 1Q; lays commercial groundwork for psilocybin therapy
COMPASS Pathways, a mental health care company focused on advancing its COMP360 psilocybin therapy for treatment-resistant depression (TRD), posted an earnings beat for the first quarter which sent its shares higher. For the quarter ended in March, the company reported...
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
Psychedelic therapies will soon be representable in medical procedure coding. That coding is a prerequisite for insurance plans to reimburse the therapies.
Imran Khan On Psychedelics - More We Don't Know Than We Do
Imran Khan is Executive Director of the Berkeley Center for the Science of Psychedelics. Research behind psychedelics - way more that we don't know than we do.
Source: https://incomestatements.info
Category: Stock Reports